Akeso Received Payment for the Development Collaboration on Tagitanlimab
Portfolio Pulse from
Akeso Inc. received payment from Sichuan Kelun for their collaboration on the development of tagitanlimab, a PD-L1 targeting antibody, after its approval by China's National Medical Products Administration.
January 22, 2025 | 7:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akeso Inc. received a payment from Sichuan Kelun for their collaboration on tagitanlimab, a PD-L1 targeting antibody, following its approval by China's NMPA.
The payment from Sichuan Kelun signifies a successful collaboration and the approval of tagitanlimab by China's NMPA is a positive regulatory milestone. This is likely to boost investor confidence in Akeso's capabilities and future prospects.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80